Meningococcal Vaccine

4 Drugs classified under this drug class

Meningococcal Vaccine. Neisseria Meningitidis Vaccine 50 mcg / 0.5 ml.
PRE-FILL. SYR. (susp. for inj.): 1,10×0.5ml. Interval of inject. accord. to instructs. of M.O.H. for IM inj.
Active immuniz. of individuals from 2 mnths. of age and older against invas. meningococcal dis. caused by Neisseria meningitidis group B.
C/I: Hypersens.

Meningococcal Vaccine, Toxoid Conjugate Vaccine. Meningococcal Serogroup A 0.4 mcg / 0.5 ml, Meningococcal Serogroup C 0.4 mcg / 0.5 ml, Meningococcal Serogroup Y 0.4 mcg / 0.5 ml, Meningococcal Serogroup W135 0.4 mcg / 0.5 ml.
VIAL (Sol. for IM Inj.): 1,5×0.5 ml. Admin. as a 0.5 mL dose by IM inj.
Do not admin. this product IV or S.C.
Primary Vaccination: In child. 9 through 23 mnths. of age, the vaccine is given as a 2-dose series three mnths. apart.
Individuals 2 through 55 yrs. of age- given as a single dose.
Booster Vaccination: A single booster dose may be given to individuals 15 through 55 yrs. of age at continued risk for meningococc. dis., if at least 4 yrs. have elapsed since the prior dose.
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococ. dis. caused by Neisseria meningitidis serogroups A, C, Y and W-135. This vaccine is approved for use in individuals 9 mnths. through 55 yrs. of age and does not prevent N meningitides serogroup B dis.
C/I: Sev. allergic react. (eg, anaphylaxis) after a previous dose of a mening. capsular polysaccharide, diphtheria toxoid- or CRM197-contain. vaccine.

Meningococcal Vaccine. Neisseria Meningitidis Vaccine 5 μg/0.5 ml.
VIAL (pwdr. and solvent for sol. for IM inj.): 1, 10, 100 × single dose (0.5ml). Should be used in accordance with available official recommend.
Primary immunisat.
Infants from 6 wks. to less than 6 mnths. of age: two doses, each of 0.5 ml, should be admin. with an interval of 2 mnths. betwn. doses.
Infants from 6 mnths. of age, child., adolesc. and adult.: a single 0.5 mL dose should be admin.
An addit. primary dose of this vaccine may be consid. appropr. for some individuals.
Booster doses: After complet. of the prim. immunisat. course in infants 6 wks. to less than 12 mnths. of age, a booster dose should be given at 12 mnths. of age with an interval of at least 2 mnths. after the last Nimenrix vaccinat.
Indicated for active immunisat. of individuals from the age of 6 wks. against invas. meningococc. dis. caused by Neisseria meningitidis group A, C, W-135 and Y.
C/I: Hypersens.

Meningococcal Vaccine. Meningococcus B, multicomponent vaccine (subfamily A1,2,3) 60 mcg, Meningococcus B, multicomponent vaccine (subfamily B1,2,3) 60 mcg.
VIAL (susp. for IM inj.): 1,5,10 × 0.5ml.
Primary series: 2 doses (0.5 ml each) admin. at a 6 mnth. interval.
3 doses: 2 doses (0.5 ml each) adm. at least 1 mnth. apart, followed by a 3^rd dose at least 4 mnths. after the 2^nd dose.
Booster dose: A booster dose should be consid. follow. either dosing regimen for individuals at continued risk of invas. meningococcal dis.
Other ped. population: not indicated for child. under 10 yrs. old.
Active immunisation of individ. 10 yrs. and older to prevent invas. meningococ. dis. caused by Neisseria meningitidis serogroup B.
The use of this vaccine should be in accordance with official recommendations.
C/I: Hypersens.